Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003133 · ClinicalTrials.gov registry record · Phase 1

Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer

A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target

NCT00003133: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00003133 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00003133, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy following surgery in treating patients with advanced bladder cancer.

Interventions

  • DRUG cisplatin
  • DRUG paclitaxel
  • BIOLOGICAL filgrastim
  • DRUG doxorubicin hydrochloride
  • DRUG gemcitabine hydrochloride

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 1997-09
Est. Completion 2003-01
Phase Phase 1
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT00003133 record still lists

NCT00003133 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).

The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.

NCT00003133 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00003133 about?

NCT00003133 is a clinical study titled "Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy following surgery in treating patients with ...

What is the current status of trial NCT00003133?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1997-09. Estimated completion is 2003-01.

What interventions are being tested in trial NCT00003133?

The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00003133?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00003133's enrollment target sits among peer trials

30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003133, the US trial registry maintained by the National Library of Medicine. NCT00003133 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.